{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:17:13Z","timestamp":1784290633367,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Bank research chair for the treatment of brain tumors"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Glioblastoma (GBM) is a difficult disease to treat for different reasons, with the blood\u2013brain barrier (BBB) preventing therapeutic drugs from reaching the tumor being one major hurdle. The median overall survival is only 14.6 months after the standard first line of treatment. At relapse, there is no recognized standard second-line treatment. Our team uses intra-arterial (IA) chemotherapy as a means to bypass the BBB, hence achieving an overall median survival of 25 months. However, most patients eventually fail the treatment and progress. This is why we wish to expand our portfolio of options in terms of chemotherapy agents available for IA administration. In this study, we tested topotecan, cytarabine, and new formulations of carboplatin and paclitaxel by IA administration in the F98-Fischer glioma-bearing rat model as a screening tool for identifying potential candidate drugs. The topotecan IA group showed increased survival compared to the intravenous (IV) group (29.0 vs. 23.5), whereas the IV cytarabine group survived longer than the IA group (26.5 vs. 22.5). The new formulation of carboplatin showed a significant increase in survival compared to two previous studies with the conventional form (37.5 vs. 26.0 and 30.0). As for paclitaxel, it was too neurotoxic for IA administration. Topotecan and the new formulation of carboplatin demonstrated significant results, warranting their transition for consideration in clinical trials.<\/jats:p>","DOI":"10.3390\/biom15030421","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T07:49:57Z","timestamp":1742197797000},"page":"421","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimization of Intra-Arterial Administration of Chemotherapeutic Agents for Glioblastoma in the F98-Fischer Glioma-Bearing Rat Model"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-4982","authenticated-orcid":false,"given":"Juliette","family":"Latulippe","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent-Olivier","family":"Roy","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Surgery, Centre Hospitalier de l\u2019Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernand","family":"Gobeil","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fortin","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Surgery, Centre Hospitalier de l\u2019Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/jcbfm.2014.14","article-title":"Impact of Drug Size on Brain Tumor and Brain Parenchyma Delivery after a Blood\u2013Brain Barrier Disruption","volume":"34","author":"Blanchette","year":"2014","journal-title":"J. Cereb. Blood Flow Metab"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The Blood-Brain Barrier: Structure, Regulation, and Drug Delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2015.05.005","article-title":"Glioblastoma multiforme: Pathogenesis and treatment","volume":"152","author":"Alifieris","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41582-022-00621-0","article-title":"Advances in local therapy for glioblastoma\u2014Taking the fight to the tumour","volume":"18","author":"Nieland","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11060-020-03435-6","article-title":"Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood\u2013brain barrier disruption: Where are we now, and where we are going","volume":"147","author":"Khatri","year":"2020","journal-title":"J. Neuro-Oncology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pinkiewicz, M., Pinkiewicz, M., Walecki, J., and Zawadzki, M. (2022). A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.950167"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fortin, D. (2019). Drug Delivery Technology to the CNS in the Treatment of Brain Tumors: The Sherbrooke Experience. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11050248"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3171\/2010.9.JNS101223","article-title":"Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma","volume":"114","author":"Boockvar","year":"2011","journal-title":"J. Neurosurg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/jnis-2023-021055","article-title":"Safety and feasibility of intra-arterial delivery of teniposide to high grade gliomas after blood\u2013brain barrier disruption: A case series","volume":"16","author":"Ruan","year":"2023","journal-title":"J. NeuroInterventional Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"vdac104","DOI":"10.1093\/noajnl\/vdac104","article-title":"Safety of intra-arterial chemotherapy with or without osmotic blood\u2013brain barrier disruption for the treatment of patients with brain tumors","volume":"4","author":"Uluc","year":"2022","journal-title":"Neuro-Oncology Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2174\/1568009615666150616123548","article-title":"Chemotherapy Delivery Strategies to the Central Nervous System: Neither Optional nor Superfluous","volume":"15","author":"Drapeau","year":"2015","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(22)00599-X","article-title":"Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: A first-in-patient, single-centre, single-arm, phase 1b trial","volume":"23","author":"Spinazzi","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000011923","article-title":"Topotecan\u2014A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience","volume":"56","author":"Kollmannsberger","year":"1999","journal-title":"Oncology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1991.9.4.679","article-title":"Cytarabine and neurologic toxicity","volume":"9","author":"Baker","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-019-03204-0","article-title":"Temporary blood\u2013brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma","volume":"144","author":"Lemaire","year":"2019","journal-title":"J. Neuro-Oncology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41467-024-45818-7","article-title":"Repeated Blood-Brain Barrier Opening with a Nine-Emitter Implantable Ultrasound Device in Combination with Car-boplatin in Recurrent Glioblastoma: A Phase I\/II Clinical Trial","volume":"15","author":"Carpentier","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/bs.podrm.2018.11.001","article-title":"Paclitaxel","volume":"Volume 44","author":"Alqahtani","year":"2019","journal-title":"Profiles of Drug Substances, Excipients and Related Methodology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s11095-009-9922-2","article-title":"Hydrogel Matrix Entrapping PLGA-Paclitaxel Microspheres: Drug Delivery with Near Zero-Order Release and Implantability Advantages for Malignant Brain Tumour Chemotherapy","volume":"26","author":"Ranganath","year":"2009","journal-title":"Pharm. Res."},{"key":"ref_20","first-page":"3441","article-title":"Polilactofate Microspheres for Paclitaxel De-livery to Central Nervous System Malignancies","volume":"9","author":"Li","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100004753","article-title":"MR-Pathological Comparison in F98-Fischer Glioma Model Using a Human Gantry","volume":"33","author":"Blanchard","year":"2006","journal-title":"Can. J. Neurol. Sci. \/ J. Can. des Sci. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijrobp.2011.10.054","article-title":"Glioblastoma Treatment: Bypassing the Toxicity of Platinum Compounds by Using Liposomal Formulation and Increasing Treatment Efficiency With Concomitant Radiotherapy","volume":"84","author":"Charest","year":"2012","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1017\/S0317167100053890","article-title":"A blood-brain barrier disruption model eliminating the hemodynamic effect of ketamine","volume":"31","author":"Fortin","year":"2004","journal-title":"Can. J. Neurol. Sci. \/ J. Can. des Sci. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Jeong, S.-H., Jang, J.-H., and Lee, Y.-B. (2020). Pharmacokinetic Comparison of Three Different Administration Routes for Topotecan Hydrochloride in Rats. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090231"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0006-8993(99)02089-2","article-title":"Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration","volume":"856","author":"Groothuis","year":"2000","journal-title":"Brain Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/ar.25083","article-title":"Defects in the expression of colonic host defense factors associate with barrier dysfunction induced by a high-fat\/high-cholesterol diet","volume":"306","author":"Valdes","year":"2022","journal-title":"Anat. Rec."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-013-1238-8","article-title":"Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain","volume":"115","author":"Charest","year":"2013","journal-title":"J. Neuro-Oncology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1017\/S0317167100006715","article-title":"Standardization and Detailed Characterization of the Syngeneic Fischer\/F98 Glioma Model","volume":"34","author":"Mathieu","year":"2007","journal-title":"Can. J. Neurol. Sci. \/ J. Can. des Sci. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4161\/cbt.25327","article-title":"Dual kinin B1 and B2 receptor activation provides enhanced blood\u2013brain barrier permeability and anticancer drug delivery into brain tumors","volume":"14","author":"Savard","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"ref_30","first-page":"195","article-title":"In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: Distribution and radiosensitisation efficacy","volume":"97","author":"Jarnet","year":"2009","journal-title":"J. Neuro-Oncology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3171\/2022.2.JNS212006","article-title":"Single low-dose targeted bevacizumab infusion in adult patients with steroid-refractory radiation necrosis of the brain: A phase II open-label prospective clinical trial","volume":"137","author":"Dashti","year":"2022","journal-title":"J. Neurosurg."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gahide, G., Vendrell, J.-F., Massicotte-Tisluck, K., Caux, S., Deschamps, S., No\u00ebl-Lamy, M., Belzile, F., Roy, L.-O., and Fortin, D. (2025). Safety of Cerebral Intra-Arterial Chemotherapy for the Treatment of Malignant Brain Tumours. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020524"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3171\/2021.3.PEDS20738","article-title":"Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: Results of a phase I trial","volume":"28","author":"McCrea","year":"2021","journal-title":"J. Neurosurgery Pediatr."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Upadhyayula, P.S., Spinazzi, E.F., Argenziano, M.G., Canoll, P., and Bruce, J.N. (2020). Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010039"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/3\/421\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:54:32Z","timestamp":1760028872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/3\/421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,16]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["biom15030421"],"URL":"https:\/\/doi.org\/10.3390\/biom15030421","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,16]]}}}